142 related articles for article (PubMed ID: 36190971)
21. Berberine ameliorates depression-like behavior in CUMS mice by activating TPH1 and inhibiting IDO1-associated with tryptophan metabolism.
Ge PY; Qu SY; Ni SJ; Yao ZY; Qi YY; Zhao X; Guo R; Yang NY; Zhang QC; Zhu HX
Phytother Res; 2023 Jan; 37(1):342-357. PubMed ID: 36089660
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity.
Zhang Y; Li Y; Chen X; Chen X; Chen C; Wang L; Dong X; Wang G; Gu R; Li F; Han F; Chen D
J Med Chem; 2022 Aug; 65(16):11214-11228. PubMed ID: 35938398
[TBL] [Abstract][Full Text] [Related]
23. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
24. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
25. Role of indoleamine 2,3-dioxygenase in health and disease.
Yeung AW; Terentis AC; King NJ; Thomas SR
Clin Sci (Lond); 2015 Oct; 129(7):601-72. PubMed ID: 26186743
[TBL] [Abstract][Full Text] [Related]
26. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
27. Trial watch: IDO inhibitors in cancer therapy.
Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
[TBL] [Abstract][Full Text] [Related]
28. Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Korac K; Rajasekaran D; Sniegowski T; Schniers BK; Ibrahim AF; Bhutia YD
Biochem J; 2022 Sep; 479(17):1807-1824. PubMed ID: 35997090
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer.
Bessede A; Peyraud F; Le Moulec S; Cousin S; Cabart M; Chomy F; Rey C; Lara O; Odin O; Nafia I; Guegan JP; Italiano A
Clin Cancer Res; 2023 Dec; 29(23):4883-4893. PubMed ID: 37756581
[TBL] [Abstract][Full Text] [Related]
30. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Odunsi K; Qian F; Lugade AA; Yu H; Geller MA; Fling SP; Kaiser JC; Lacroix AM; D'Amico L; Ramchurren N; Morishima C; Disis ML; Dennis L; Danaher P; Warren S; Nguyen VA; Ravi S; Tsuji T; Rosario S; Zha W; Hutson A; Liu S; Lele S; Zsiros E; McGray AJR; Chiello J; Koya R; Chodon T; Morrison CD; Putluri V; Putluri N; Mager DE; Gunawan R; Cheever MA; Battaglia S; Matsuzaki J
Sci Transl Med; 2022 Mar; 14(636):eabg8402. PubMed ID: 35294258
[TBL] [Abstract][Full Text] [Related]
31. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors.
Lawson MA; Parrott JM; McCusker RH; Dantzer R; Kelley KW; O'Connor JC
J Neuroinflammation; 2013 Jul; 10():87. PubMed ID: 23866724
[TBL] [Abstract][Full Text] [Related]
32. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
[TBL] [Abstract][Full Text] [Related]
33. NO
Wang L; Tang W; Yang S; He P; Wang J; Gaedcke J; Ströbel P; Azizian A; Ried T; Gaida MM; Yfantis HG; Lee DH; Lal A; Van den Eynde BJ; Alexander HR; Ghadimi BM; Hanna N; Hussain SP
Int J Cancer; 2020 Jun; 146(11):3160-3169. PubMed ID: 31609478
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
35. T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation.
Yang T; Li QQ; Liu YM; Yang B
World J Gastroenterol; 2023 May; 29(17):2701-2703. PubMed ID: 37213408
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive behavioral analysis of indoleamine 2,3-dioxygenase knockout mice.
Hirata N; Hattori S; Shoji H; Funakoshi H; Miyakawa T
Neuropsychopharmacol Rep; 2018 Sep; 38(3):133-144. PubMed ID: 30175526
[TBL] [Abstract][Full Text] [Related]
37. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans.
Kiank C; Zeden JP; Drude S; Domanska G; Fusch G; Otten W; Schuett C
PLoS One; 2010 Jul; 5(7):e11825. PubMed ID: 20689575
[TBL] [Abstract][Full Text] [Related]
38. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
39. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
40. Pulsatilla chinensis saponins ameliorated murine depression by inhibiting intestinal inflammation mediated IDO1 overexpression and rebalancing tryptophan metabolism.
Wang T; Song Y; Ai Z; Liu Y; Li H; Xu W; Chen L; Zhu G; Yang M; Su D
Phytomedicine; 2023 Jul; 116():154852. PubMed ID: 37167824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
